Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $99 price target and named it a top pick among small-to-mid cap biotech stocks. The firm is “bullish” on the Myqorzo launch in obstructive hypertrophic cardiomyopathy and sees its optionality in nonobstructive disease as “still underappreciated,” the analyst tells investors. Fuller Phase 3 ACACIA-HCM data are expected to drive mid-term upside, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $97 from $92 at JPMorgan
- Cytokinetics announces new data related to Myqorzo at ESC Heart Failure 2026
- Cytokinetics price target raised to $140 from $136 at H.C. Wainwright
- Cytokinetics Raises $760 Million in Stock Offering
- Cytokinetics price target raised to $105 from $95 at Wells Fargo